For almost 10 years, we have successfully marketed the calcium antagonist Zanidip® (lercanidipine) in Switzerland. In 2012, Zanipress®, a fixed combination with lercanidipine and enalapril (ACE inhibitor), was launched. Zanidip® and Zanipress® are effective, well tolerated and easy to use on a daily basis.
We would like to inform you that as of November 1, 2014, the prices of Zanidip® and Zanipress® will be reduced. Zanidip
®
will be reduced by 23% and Zanipress
®
by 5%.
For more information, please visit: www.swissmedicinfo.ch
Pierre Fabre Pharma AG, Hegenheimermattweg 183, 4123 Allschwil.
